Omalizumab for atopic dermatitis: evidence for and against its use
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Omalizumab for atopic dermatitis: evidence for and against its use. / Holm, Jesper G.; Thomsen, Simon F.
I: Giornale Italiano di Dermatologia e Venereologia, Bind 154, Nr. 4, 2019, s. 480-487.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Omalizumab for atopic dermatitis: evidence for and against its use
AU - Holm, Jesper G.
AU - Thomsen, Simon F.
PY - 2019
Y1 - 2019
N2 - INTRODUCTION: Omalizumab, has been used for almost two decades, mainly in allergic asthma and chronic spontaneous urticaria for which it is highly beneficial. Smaller studies have evaluated the effects of omalizumab in atopic dermatitis (AD). Current treatments options, such as cyclosporine and azathioprine have limited effect on AD and numerous side effects. The recently introduced biologic dupilumab (anti-IL4) shows promising results, however with conjunctivitis as a prevalent side effect. We evaluate the current evidence for the use of omalizumab in AD. EVIDENCE ACQUISITION: Systematic literature searches were performed in PubMed, Web of Science, Embase and Clinicaltrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. EVIDENCE SYNTHESIS: Thirty-four studies (12 single case studies, 15 case series, 5 prospective studies and 2 small pilot randomized placebo-controlled trials [RCTs]), including a total of 214 patients with median of 3, ranging from 1-35 patients were identified. A total of 169 patients (79.0%) experienced a beneficial effect from treatment, ranging from little to complete response, whereas 45 patients (21.0%) reported no or negative effect from omalizumab treatment. CONCLUSIONS: Omalizumab is a safe and well-tolerated treatment with some clinical benefit in AD patients. However, the lack of larger RCTs and possible publication bias limit the recommendation of omalizumab for use in clinical practice for AD. Newer and more effective treatments exist and should be prioritized.
AB - INTRODUCTION: Omalizumab, has been used for almost two decades, mainly in allergic asthma and chronic spontaneous urticaria for which it is highly beneficial. Smaller studies have evaluated the effects of omalizumab in atopic dermatitis (AD). Current treatments options, such as cyclosporine and azathioprine have limited effect on AD and numerous side effects. The recently introduced biologic dupilumab (anti-IL4) shows promising results, however with conjunctivitis as a prevalent side effect. We evaluate the current evidence for the use of omalizumab in AD. EVIDENCE ACQUISITION: Systematic literature searches were performed in PubMed, Web of Science, Embase and Clinicaltrials.gov to identify any study (case reports, case series, and controlled trials) evaluating the effect of treatment with omalizumab in AD. EVIDENCE SYNTHESIS: Thirty-four studies (12 single case studies, 15 case series, 5 prospective studies and 2 small pilot randomized placebo-controlled trials [RCTs]), including a total of 214 patients with median of 3, ranging from 1-35 patients were identified. A total of 169 patients (79.0%) experienced a beneficial effect from treatment, ranging from little to complete response, whereas 45 patients (21.0%) reported no or negative effect from omalizumab treatment. CONCLUSIONS: Omalizumab is a safe and well-tolerated treatment with some clinical benefit in AD patients. However, the lack of larger RCTs and possible publication bias limit the recommendation of omalizumab for use in clinical practice for AD. Newer and more effective treatments exist and should be prioritized.
KW - Omalizumab
KW - Anti-IgE antibodies
KW - Dermatitis, atopic
U2 - 10.23736/S0392-0488.19.06302-8
DO - 10.23736/S0392-0488.19.06302-8
M3 - Review
C2 - 30717578
VL - 154
SP - 480
EP - 487
JO - Minerva dermatologica
JF - Minerva dermatologica
SN - 0026-4741
IS - 4
ER -
ID: 226037174